Prokidney Corp. ( (PROK) ) has released its Q2 earnings. Here is a breakdown of the information Prokidney Corp. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ProKidney Corp. is a biotechnology company focused on developing treatments to preserve kidney function in patients with chronic kidney disease, operating primarily in the healthcare sector. In its latest earnings report for the quarter ended June 30, 2025, ProKidney Corp. reported a net loss of $36.97 million, compared to a net loss of $38.47 million in the same period last year. The company generated revenue of $221,000 for the quarter, marking a significant improvement from zero revenue in the previous year, primarily from leasing activities. Operating expenses decreased slightly to $39.93 million from $43.06 million, with research and development costs being the largest component. Despite the net loss, the company saw an increase in its cash and cash equivalents to $84.94 million, although this was a decrease from $99.12 million at the end of 2024. Looking ahead, ProKidney Corp. remains focused on advancing its clinical trials and exploring strategic opportunities to enhance shareholder value, while managing its financial resources prudently.